Accéder au contenu
Merck

Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation.

Nature cell biology (2015-09-22)
Yinghui Li, Qi-Ling Zhou, Wenjie Sun, Prashant Chandrasekharan, Hui Shan Cheng, Zhe Ying, Manikandan Lakshmanan, Anandhkumar Raju, Daniel G Tenen, Shi-Yuan Cheng, Kai-Hsiang Chuang, Jun Li, Shyam Prabhakar, Mengfeng Li, Vinay Tergaonkar
RÉSUMÉ

Transcriptional reactivation of TERT, the catalytic subunit of telomerase, is necessary for cancer progression in about 90% of human cancers. The recent discovery of two prevalent somatic mutations-C250T and C228T-in the TERT promoter in various cancers has provided insight into a plausible mechanism of TERT reactivation. Although the two hotspot mutations create a similar binding motif for E-twenty-six (ETS) transcription factors, we show that they are functionally distinct, in that the C250T unlike the C228T TERT promoter is driven by non-canonical NF-κB signalling. We demonstrate that binding of ETS to the mutant TERT promoter is insufficient in driving its transcription but this process requires non-canonical NF-κB signalling for stimulus responsiveness, sustained telomerase activity and hence cancer progression. Our findings highlight a previously unrecognized role of non-canonical NF-κB signalling in tumorigenesis and elucidate a fundamental mechanism for TERT reactivation in cancers, which if targeted could have immense therapeutic implications.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Millipore
ANTI-FLAG® antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Anti-TRF2 Antibody, clone 4A794, clone 4A794, Upstate®, from mouse